The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWAND.L Regulatory News (WAND)

  • There is currently no data for WAND

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed Director Dealings and Issue of Equity

23 Jul 2020 16:28

RNS Number : 9346T
WANdisco Plc
23 July 2020
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION, RELEASE, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL. THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS FOR INFORMATION PURPOSES ONLY AND SHALL NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE OR ACQUIRE ANY SECURITIES IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA (UNLESS AN EXEMPTION UNDER THE RELEVANT SECURITIES LAWS IS AVAILABLE) OR IN ANY OTHER JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.

 

This Announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Upon the publication of this Announcement, this inside information is now considered to be in the public domain.

 

23 July 2020

WANdisco plc

("WANdisco" or the "Company")

 

Proposed Director Dealings and Issue of Equity

 

Certain Directors and employees of the Company (together, the "Selling Shareholders"), have today indicated their intention to sell up to approximately 993,758 ordinary shares in the Company at 500 pence per share ("Vendor Placing") following the release of Restricted Stock Units ("RSUs") vesting under the Company's options schemes (together, the "Vendor Placing Shares"), representing up to approximately 1.9 per cent. of the Company's existing issued ordinary share capital.

 

A full schedule of the Selling Shareholders that are persons discharging managerial responsibilities ("PDMR") can be found at the base of this announcement. Under the Vendor Placing, the PDMRs are intending to sell up to 514,104 ordinary shares and the other employees up to 479,654 ordinary shares. The PDMR's have advised the Company that their sales of ordinary shares in the Company are in part to cover their costs of the RSU release and associated taxes and that they intend to retain 25 per cent. of vested post tax shares. Following the sale, they would in aggregate hold 4,698,899 ordinary shares, representing 9.2 per cent. of the Company's existing issued ordinary share capital (an increase from 9.1 per cent.).

 

The Selling Shareholders that are PDMRs have undertaken that, without the prior written consent of Stifel Nicolaus Europe Limited ("Stifel"), neither they, nor any persons closely associated with them, will dispose of any further ordinary shares for a period of six months after completion of the sale (subject to customary exceptions).

 

It is intended that the Vendor Placing Shares will be offered to certain institutional investors.

 

The results of the Vendor Placing will be announced as soon as practicable.

 

Schedule of the Company's PDMRs intending to sell ordinary shares in the Vendor Placing:

 

PDMR

Role

David Richards

Chairman, CEO and Co-founder

Yeturu Aahlad

Chief Scientist, Inventor & Co-Founder (Director)

Erik Miller

Chief Financial Officer

Bob Corey

Non-executive Director

Karl Monaghan

Non-executive Director

 

 

For further information, please contact:

 

WANdisco plc

Via FTI Consulting

David Richards, Chief Executive Officer and Chairman

 

Erik Miller, Chief Financial Officer

 

 

 

FTI Consulting

+44 (0)20 3727 1137

Matt Dixon / Chris Birt / Kwaku Aning

 

 

 

Stifel (Nomad)

+44 (0)20 7710 7600

Fred Walsh / Rajpal Padam

 

 

 

About WANdisco

WANdisco is the LiveData company for machine learning and AI. WANdisco solutions enable enterprises to create an environment where data is always available, accurate and protected, creating a strong backbone for their IT infrastructure and a bedrock for running consistent, accurate machine learning applications. With zero downtime and zero data loss, WANdisco Fusion keeps geographically dispersed data at any scale consistent between on-premises and cloud environments allowing businesses to operate seamlessly in a hybrid or multi-cloud environment. WANdisco has over a hundred customers and significant go-to-market partnerships with Microsoft Azure, Amazon Web Services, Google Cloud, Oracle, and others as well as OEM relationships with IBM and Alibaba.

 

For additional information, please visit www.wandisco.com 

 

 

This announcement contains inside information as defined in Article 7 of the Market Abuse Regulation No. 596/2014 ("MAR"). Market Soundings, as defined in MAR, were taken in respect of the proposed Vendor Placing with the result that certain persons became aware of this inside information, as permitted by MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain. The person responsible for arranging for the release of this announcement on behalf of WANdisco is David Richards, Chief Executive Officer and Chairman of WANdisco.

 

 IMPORTANT NOTICES 

This Announcement or any part of it does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities in the United States (including its territories and possessions, any state of the United States and the District of Columbia). The Vendor Placing Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "US Securities Act") or with any securities regulatory authority of any state or jurisdiction of the United States, and may not be offered, sold or transferred, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There will be no public offering of securities in the United States.

This Announcement may contain and the Company may make verbal statements containing "forward-looking statements" with respect to certain of the Company's plans and its current goals and expectations relating to its future financial condition, performance, strategic initiatives, objectives and results. By their nature, all forward-looking statements involve risk and uncertainty because they relate to future events and circumstances which are beyond the control of the Company, including amongst other things, United Kingdom domestic and global economic business conditions, market-related risks such as fluctuations in interest rates and exchange rates, the policies and actions of governmental and regulatory authorities, the effect of competition, inflation, deflation, the timing effect and other uncertainties of future acquisitions or combinations within relevant industries, the effect of tax and other legislation and other regulations in the jurisdictions in which the Company and its respective affiliates operate, the effect of volatility in the equity, capital and credit markets on the Company's profitability and ability to access capital and credit, a decline in the Company's credit ratings; the effect of operational risks; and the loss of key personnel. As a result, the actual future financial condition, performance and results of the Company may differ materially from the plans, goals and expectations set forth in any forward-looking statements. Any forward-looking statements made in this Announcement by or on behalf of the Company speak only as of the date they are made. Except as required by applicable law or regulation, the Company expressly disclaims any obligation or undertaking to publish any updates or revisions to any forward-looking statements contained in this Announcement to reflect any changes in the Company's expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based.

Solely for the purposes of Article 9(8) of Commission Delegated Directive 2017/593 (the "Delegated Directive") regarding the responsibilities of Manufacturers under the Product Governance requirements contained within: (a) Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of the Delegated Directive; and (c) local implementing measures (the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Ordinary Shares have been subject to a product approval process, which has determined that the Ordinary Shares are (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, Distributors (as defined within the MiFID II Product Governance Requirements) should note that: the price of the Ordinary Shares may decline and investors could lose all or part of their investment; the Ordinary Shares offer no guaranteed income and no capital protection; and an investment in Ordinary Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the proposed placing. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability of appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Ordinary Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Ordinary Shares and determining appropriate distribution channels.

Stifel is regulated by the Financial Conduct Authority (the "FCA") in the United Kingdom and is acting exclusively for the Company and no one else, and Stifel will not be responsible to anyone (including any purchasers of the Vendor Placing Shares) other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Vendor Placing or any other matters referred to in this Announcement.

No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Stifel or by any of its respective affiliates or agents as to, or in relation to, the accuracy or completeness of this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHPPUCPMUPUGAW
Date   Source Headline
4th Oct 20237:00 amRNSWANdisco plc rebrands as Cirata plc
22nd Sep 20236:24 pmRNSHolding(s) in Company
11th Sep 20237:00 amRNSInterim results
7th Sep 20233:30 pmRNSNotice of Results
30th Aug 20236:04 pmRNSResult of Annual General Meeting
18th Aug 20236:05 pmRNSBlock Admission Notification
16th Aug 20238:07 amRNSGM Signs Multi-Project Contract with WANdisco
31st Jul 20237:00 amRNSHolding(s) in Company
28th Jul 20233:25 pmRNSHolding(s) in Company
26th Jul 20237:00 amRNSBoard Changes
25th Jul 20237:30 amRNSRestoration - WANdisco plc
25th Jul 20237:00 amRNSConfirmation of Exchange Rate
24th Jul 202310:45 amRNSResult of GM
17th Jul 20235:00 pmRNSPosting of Annual Report and Accounts
12th Jul 20231:45 pmRNSPublication of Annual Report and Accounts
11th Jul 20237:00 amRNSContract Win
10th Jul 20237:00 amRNSContract Renewal
7th Jul 20237:00 amRNSConfirmation of Fundraise
5th Jul 20236:29 pmRNSPublication of Notice of General Meeting
5th Jul 202311:30 amRNSUpdate to Fundraise Timetable
4th Jul 20237:00 amRNSResult of Fundraising
3rd Jul 202312:00 pmRNSLaunch of Fundraise
29th Jun 20237:00 amRNSPreliminary Unaudited Results FY22
28th Jun 202311:51 amRNSUpdate on Timing of Results and Equity Issue
26th Jun 20233:30 pmRNSTurnaround Plan Momentum
26th Jun 20237:00 amRNSWANdisco Signs New Agreement with Accenture
15th Jun 20239:46 amRNSFCA investigation timeline update
9th Jun 20237:00 amRNSSuccessful Shareholder General Meeting Next Steps
6th Jun 20233:49 pmRNSResult of General Meeting
19th May 20236:22 pmRNSPublication of Circular and Notice of GM
19th May 20236:04 pmRNSBoard Change
15th May 20237:00 amRNSExploring Funding Options
9th May 20235:30 pmRNSWANdisco
9th May 20237:00 amRNSAppointment of Interim Chief Executive
4th May 20237:00 amRNSOrganisation Update
28th Apr 20237:00 amRNSIndependent Investigation Update
20th Apr 20237:00 amRNSFCA Investigation
5th Apr 20237:00 amRNSExecutive Chair Appointment Confirmation
4th Apr 20237:00 amRNSContract Renewals
3rd Apr 20237:00 amRNSBoard Change and Investigation Update
22nd Mar 20237:00 amRNSAppointment of Interim Chair
10th Mar 20239:31 amRNSIndependent Investigation Appointment
9th Mar 20237:30 amRNSSuspension - WANdisco plc
9th Mar 20237:00 amRNSTrading Revision
7th Mar 20237:00 amRNSAppointment of Joint Broker
6th Mar 20237:00 amRNSResponse to press speculation
1st Mar 20238:16 amRNSTotal Voting Rights
1st Feb 20234:05 pmRNSTotal Voting Rights
24th Jan 20237:00 amRNS$9m industrial and consumer goods contract win
11th Jan 20237:00 amRNSFY22 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.